Search PubMed⌕ Search

Biomedical subjects

S Steinberg

Publications and source records attributed to S Steinberg.

At least 127 records · Page 7Linked to original sources
PubMed1983

An open dose finding study of melperone in treatment of agitation and irritability associated with dementia.

Seventeen older patients with a diagnosis of Organic Brain Syndrome were placed on a four-week trial of melperone for treatment of behavioural disturbances associated with dementia. Efficacy evaluation of the drug revealed improved ratings of the patients in the areas of agitation/irritability, anxiety, unsociability, and mental alertness. Thirteen of the fourteen patients who completed the trial were rated generally as showing at least minimal improvement while on the drug. There were no serious side effects noted, with drowsiness the most frequent finding. These favourable results are suggestive of the usefulness of this drug, and point to the need for double-blind, comparative studies.

Aged↗
PubMed1982

Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.

1. Type I risk factor for tardive dyskinesia is defined as a risk leading primarily to a reversible form, while Type II factors to irreversible forms. 2. Central anticholinergic drugs appear as the prototype of Type I drug factor which increased the clinical manifestations of the disorder, but not its overall incidence. 3. Clinical investigations of dopamine agonists suggest an important role for them in clinical management and understanding of neuroleptic-induced supersensitivity disorder. 4. We would like to propose a new classification of neuroleptics. Type I neuroleptics (estrogens, diphenylbutylpiperidines) are associated with milder and reversible dyskinesia, while Type II (Classical neuroleptics) with severe and irreversible forms.

Animals↗
PubMed1980

Varicella-zoster-associated encephalitis: detection of specific antibody in cerebrospinal fluid.

Varicella-zoster (VZ) antibody measured by indirect immunofluorescence was used to identify patients with encephalitis due to VZ virus. In 15 of 16 (94%) patients with VZ infection and clinical evidence of central nervous system involvement, VZ antibody was present at a titer of 1:2 or greater in cerebrospinal fluid. In contrast, no VZ antibody was detected in the cerebrospinal fluid of seven patients with VZ infections without clinical signs of central nervous system involvement, nor was any detected in the cerebrospinal fluid of 25 patients with malignant or demyelinating disease or encephalitis due to other viral or toxic agents. All of these patients had detectable serum VZ antibody. Thus, in this study the presence of detectable VZ antibody in cerebrospinal fluid measured by indirect immunofluorescence seemed to correlate with clinical evidence of central nervous system involvement due to this virus.

Antibodies, Viral↗
PubMed1979

Diabetic ketoalkalosis.

The usual metabolic derangement in uncontrolled diabetes mellitus is metabolic acidosis, with an increase in the anion gap because of increased ketoacids and lactate. However, diabetic ketoalkalosis may occasionally be encountered, the prominent clinical feature of which is vomiting, with depletion of potassium, chloride, and hydrogen ions. Self-medication with absorbabe alkali may also contribute to the alkalosis. It would be dangerous to treat hyperlgycemic patients with alkali if their condition is ketoalkalosis instead of ketoacidosis.

Alkalosis↗
PubMed1978

Antibody to varicella-zoster virus after passive immunization against chickenpox.

Antibody titers to varicella-zoster virus were measured in varicella-susceptible immunocompromised children 48 h after they received either one of two lots of zoster immune globulin (ZIG) or a selected lot of immune serum globulin (ISG). Globulin was given to modify varicella in these children after exposure to varicella or zoster. Indirect immunofluorescence antibody titers (FAMA) of children after receipt of globulin ranged from less than 1:2 to 1:32. Geometric mean FAMA titers were highest after 1.2 ml of ISG per kg (FAMA titer 1:128) and 0.16 ml of ZIG lot A per kg (FAMA titer 1:1,024). Selected batches of ISG titering 1:128 or greater by FAMA, at a dose of 1.2 ml/kg, may be used to attempt to modify varicella in susceptible high-risk individuals when ZIG is not available.

Antibodies, Viral↗
PubMed1977

Immune adherence hemagglutination: further observations on demonstration of antibody to varicella-zoster virus.

The immune adherence hemagglutination test for measurement of antibody to varicella-zoster (V-Z) virus is well suited to performance in a routine serology laboratory. This test is useful in assessing susceptibility to varicella, measuring antibody to V-Z virus in globulin preparations, and evaluating some effects of passive immunization. Since the complement-fixation test for antibody to V-Z virus lacks sensitivity and the fluorescent antibody to membrane antigen test is not readily available, the immune adherence hemagglutination test may be of practical value in patient management.

Antibodies, Viral↗
PubMed1976

Cell-mediated immunity to varicella-zoster virus demonstrated by viral inactivation with human leukocytes.

Cell-mediated immunity to varicella-zoster (V-Z) virus in persons immune to varicella has been demonstrated, using a tissue culture technique. Cell-mediated immunity was reflected by the ability of peripheral leukocytes (lymphocytes and monocytes) from human donors to inactivate V-Z virus. Leukocytes were stimulated by the addition of noninfectious V-Z antigen to cultures newly infected with V-Z virus. Several days leter, the V-Z virus in these cultures was titered. When leukocytes from donors immune to caricella were used, a significant decrease in V-Z titer, compared with controls, was noted. When leukocytes from donors susceptible to varicella were tested, no decrease in V-Z virus titer was found. A mixed population of lymphocytes and monocytes from immune donors was required to demonstrate inactivation of V-Z virus. The development of specific cell-mediated immunity to V-Z virus may play a role in termination of varicella and in prevention of second attacks of this disease.

Antigens, Viral↗
PubMed1976

Detection of antibody to Varicella-Zoster virus by immune adherence hemagglutination.

A serologic test for measurement of antibody to V-Z virus by immune adherence hemagglutination is described. Initial evaluation of the test has shown it to be highly sensitive, specific, rapid, and simple to perform. The V-Z antigen may be stored at -70 degrees, and the test could be performed in any routine serology laboratory.

Antibodies, Viral↗
PubMed1976

Antibody to Varicella-Zoster virus in parturient women and their offspring during the first year of life.

A nursery outbreak of varicella is reported. Serum from 200 parturient women and 131 of their offspring were studied for antibody to varicella-zoster (V-Z) virus to analyze their immunity to varicella. Antibody titers were measured by the sensitive fluorescent antibody to membrane antigen (FAMA) technique. It was found that approximately 5% to 16% of women of child-bearing age in New York City are susceptible to varicella. Women from Puerto Rico or other subtropical and tropical areas are more likely to be susceptible (16%) than others (5%). Infants born to mothers with detectable V-Z FAMA titers almost always had detectable V-Z antibody at birth. In serial serum specimens obtained from 67 initially seropositive babies during the first year of life, it was found that by 6 months of age most infants were no longer passively protected against varicella. These observations may explain why varicella is not uncommonly observed in young babies.

Adult↗
PubMed1975

Varicella-Zoster Immunoglobulins during Varicella, Latency, and Zoster.

Antibodies to membrane antigens of cells infected by varicella-zoster virus were detected by immunofluorescence. Rises in varicella-zoster IgA, IgG, and tigM were detected after both varicella and zoster. Prompt antibody responses were observed in patients with generalized zoster as well as in those with localized zoster. A delayed response was found, moreover, in one patient who did not develop disseminated disease. Antibody to varicella-zoster virus was detected in the sera of all three patients tested prior to and in all but one of 63 patients tested soon after onset of zoster. The level of varicella-zoster IgA and IgG rose in two of three immune patients after household exposure to infection with varicella-zoster virus. Varicella-zoster IgG was detected in the cord blood of infants whose mothers were immune to varicella.

Adolescent↗